Efavirenz as a potential drug for the treatment of triple-negative breast cancers

被引：0
|
作者：
P.-T. Chiou
S. Ohms
P. G. Board
J. E. Dahlstrom
D. Rangasamy
M. G. Casarotto
机构：
[1] The Australian National University,ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research
[2] The Australian National University,The John Curtin School of Medical Research
[3] The Australian National University,Anatomical Pathology, ACT Pathology, Canberra Hospital and ANU Medical School, ANU College of Health and Medicine
来源：
Clinical and Translational Oncology | 2021年 / 23卷
关键词：
Triple-negative breast cancer; Efavirenz; LINE-1; Retrotransposon; Fatty acid metabolism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 363
页数：10
相关论文
共 50 条
  • [31] Triple-negative breast cancer and the potential for targeted therapy
    Jhan, Jing-Ru
    Andrechek, Eran R.
    PHARMACOGENOMICS, 2017, 18 (17) : 1595 - 1609
  • [32] Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers
    Seitz, S.
    Rick, F. G.
    Schally, A. V.
    Treszl, A.
    Hohla, F.
    Szalontay, L.
    Zarandi, M.
    Ortmann, O.
    Engel, J. B.
    Buchholz, S.
    ONCOLOGY REPORTS, 2013, 30 (01) : 413 - 418
  • [33] Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers
    Wang, Lei
    Lang, Guan-Tian
    Xue, Meng-Zhu
    Yang, Liu
    Chen, Li
    Yao, Ling
    Li, Xiao-Guang
    Wang, Peng
    Hu, Xin
    Shao, Zhi-Ming
    THERANOSTICS, 2020, 10 (23): : 10531 - 10547
  • [34] Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
    Linklater, Erik S.
    Tovar, Elizabeth A.
    Essenburg, Curt J.
    Turner, Lisa
    Madaj, Zachary
    Winn, Mary E.
    Melnik, Marianne K.
    Korkaya, Hasan
    Maroun, Christiane R.
    Christensen, James G.
    Steensma, Matthew R.
    Boerner, Julie L.
    Graveel, Carrie R.
    ONCOTARGET, 2016, 7 (43) : 69903 - 69915
  • [35] Therapeutic options for triple-negative breast cancers with defective homologous recombination
    Jaspers, Janneke E.
    Rottenberg, Sven
    Jonkers, Jos
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1796 (02): : 266 - 280
  • [36] Targeted chemotherapy for triple-negative breast cancers via LHRH receptor
    Foest, Crispin
    Duwe, Francesca
    Hellriegel, Martin
    Schweyer, Stefan
    Emons, Guenter
    Gruendker, Carsten
    ONCOLOGY REPORTS, 2011, 25 (05) : 1481 - 1487
  • [37] The advance of adjuvant treatment for triple-negative breast cancer
    Ge, Jingyu
    Zuo, Wenjia
    Chen, Yiyu
    Shao, Zhiming
    Yu, Keda
    CANCER BIOLOGY & MEDICINE, 2022, 19 (02) : 187 - 201
  • [38] Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
    Wesolowski, Jakub
    Tankiewicz-Kwedlo, Anna
    Pawlak, Dariusz
    CANCERS, 2022, 14 (16)
  • [39] Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers
    Kozin, Sergey V.
    Maimon, Nir
    Wang, Rong
    Gupta, Nisha
    Munn, Lance
    Jain, Rakesh K.
    Garkavtsev, Igor
    ONCOTARGET, 2017, 8 (65) : 108292 - 108302
  • [40] Updates in the treatment of basal/triple-negative breast cancer
    Shastry, Mythili
    Yardley, Denise A.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2013, 25 (01) : 40 - 48
12345